BACKGROUND: Impaired kidney function, as measured by serum cystatin C, is associated with risk of incident heart failure. Whether cystatin C is associated with preclinical cardiac structural abnormalities is unknown. We evaluate whether cystatin C is associated with left ventricular hypertrophy, diastolic dysfunction, and systolic dysfunction among 818 outpatients with coronary artery disease who were free of clinical heart failure. METHODS AND RESULTS: The 818 study participants were categorized into quartiles based on serum cystatin C concentrations, with < or =0.91 mg/L constituting the lowest quartile (I) and > or =1.28 mg/L constituting the highest (IV). Left ventricular hypertrophy (left ventricular mass index >90 g/m(2) by truncated ellipsoid method), diastolic dysfunction (impaired relaxation, pseudo-normal, or restrictive filling patterns) and systolic dysfunction (left ventricular ejection fraction < or =50%) were determined by echocardiography. Left ventricular hypertrophy was present in 68% of participants in quartile IV, compared with 44% of those in quartile I (adjusted odds ratio [OR] 2.17; 95% confidence interval [CI] 1.34 to 3.52; P = .002). Diastolic dysfunction was present in 52% of participants in quartile IV, compared with 24% of those in quartile I (adjusted OR 1.79; 95% CI 1.04 to 3.11; P = .04). Systolic dysfunction was present in 12% of those in quartile IV, compared with 6% of those in quartile I (adjusted OR 1.83; 95% CI 0.75 to 4.46; P = .15). CONCLUSION: Higher cystatin C concentrations are strongly associated with left ventricular hypertrophy and diastolic dysfunction in outpatients with coronary artery disease and without heart failure.
BACKGROUND: Impaired kidney function, as measured by serum cystatin C, is associated with risk of incident heart failure. Whether cystatin C is associated with preclinical cardiac structural abnormalities is unknown. We evaluate whether cystatin C is associated with left ventricular hypertrophy, diastolic dysfunction, and systolic dysfunction among 818 outpatients with coronary artery disease who were free of clinical heart failure. METHODS AND RESULTS: The 818 study participants were categorized into quartiles based on serum cystatin C concentrations, with < or =0.91 mg/L constituting the lowest quartile (I) and > or =1.28 mg/L constituting the highest (IV). Left ventricular hypertrophy (left ventricular mass index >90 g/m(2) by truncated ellipsoid method), diastolic dysfunction (impaired relaxation, pseudo-normal, or restrictive filling patterns) and systolic dysfunction (left ventricular ejection fraction < or =50%) were determined by echocardiography. Left ventricular hypertrophy was present in 68% of participants in quartile IV, compared with 44% of those in quartile I (adjusted odds ratio [OR] 2.17; 95% confidence interval [CI] 1.34 to 3.52; P = .002). Diastolic dysfunction was present in 52% of participants in quartile IV, compared with 24% of those in quartile I (adjusted OR 1.79; 95% CI 1.04 to 3.11; P = .04). Systolic dysfunction was present in 12% of those in quartile IV, compared with 6% of those in quartile I (adjusted OR 1.83; 95% CI 0.75 to 4.46; P = .15). CONCLUSION: Higher cystatin C concentrations are strongly associated with left ventricular hypertrophy and diastolic dysfunction in outpatients with coronary artery disease and without heart failure.
Authors: E Coll; A Botey; L Alvarez; E Poch; L Quintó; A Saurina; M Vera; C Piera; A Darnell Journal: Am J Kidney Dis Date: 2000-07 Impact factor: 8.860
Authors: Mary S Beattie; Michael G Shlipak; Haiying Liu; Warren S Browner; Nelson B Schiller; Mary A Whooley Journal: Circulation Date: 2003-01-21 Impact factor: 29.690
Authors: Kirsten Bibbins-Domingo; Maria Ansari; Nelson B Schiller; Barry Massie; Mary A Whooley Journal: Circulation Date: 2003-12-08 Impact factor: 29.690
Authors: Thomas J Wang; Jane C Evans; Emelia J Benjamin; Daniel Levy; Elizabeth C LeRoy; Ramachandran S Vasan Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: Bernice Ruo; John S Rumsfeld; Mark A Hlatky; Haiying Liu; Warren S Browner; Mary A Whooley Journal: JAMA Date: 2003-07-09 Impact factor: 56.272
Authors: Joachim H Ix; Michael G Shlipak; Haiying H Liu; Nelson B Schiller; Mary A Whooley Journal: J Am Soc Nephrol Date: 2003-12 Impact factor: 10.121
Authors: Matthew Nayor; Martin G Larson; Na Wang; Rajalakshmi Santhanakrishnan; Douglas S Lee; Connie W Tsao; Susan Cheng; Emelia J Benjamin; Ramachandran S Vasan; Daniel Levy; Caroline S Fox; Jennifer E Ho Journal: Eur J Heart Fail Date: 2017-02-20 Impact factor: 15.534
Authors: Joachim H Ix; Ian H de Boer; Christina L Wassel; Michael H Criqui; Michael G Shlipak; Mary A Whooley Journal: Circulation Date: 2010-03-08 Impact factor: 29.690
Authors: W H Wilson Tang; Kevin Shrestha; Zhili Shao; Allen G Borowski; Richard W Troughton; James D Thomas; Allan L Klein Journal: Am J Cardiol Date: 2011-05-19 Impact factor: 2.778
Authors: Joachim H Ix; Ronit Katz; Bryan Kestenbaum; Linda F Fried; Holly Kramer; Catherine Stehman-Breen; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2008-01-30 Impact factor: 10.121
Authors: Ravi Retnakaran; Philip W Connelly; Stewart B Harris; Bernard Zinman; Anthony J G Hanley Journal: Pediatr Nephrol Date: 2007-03-30 Impact factor: 3.714